I doubt RAC would exist as an oncology company advancing bisantrene today if I hadn’t called up Peter Malloy in 2019. At the time Race had no cash, the named patient program had not been a success, Biosynergy had not found a buyer for bisantrene, and the MC was around $3 million. It was not surprising the shareholders at the time were feeling grim.
I doubt RAC would exist as an oncology company advancing...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.000(0.00%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 873 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 240 | 1 |
View Market Depth
| Last trade - 07.25am 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable